Rasburicase is an antihyperuricemic drug that belongs to the category of medicines known as uricolytic agents. It was approved by the U.S. FDA on 12th of July 2002 to treat high uric acid levels in chemotherapy.

Rasburicase is used to prevent or treat hyperuricemia that can occur as a result of cancer chemotherapy.

The medicine will be administered to you by a healthcare professional in a hospital setting. Rasburicase is given as an injection into a vein (intravenous infusion) over a period of 30 minutes, once a day for up to 5 days. The dose, route of administration, and frequency will be decided by your doctor based on your disease condition and other factors. 

The common side effects that are likely to occur while you are on the treatment with Rasburicase are swelling of face, wheezing problems, headache, anxiety, abdominal pain, constipation and rashes. Some serious side effects also include high levels of liver enzymes in the blood and hypersensitivity reactions. If you experience any allergic or unusual reactions after taking this medicine, report to your doctor immediately.

It is not recommended to take Rasburicase injection if you are allergic to Rasburicase or any of its ingredients. In patients with G6PD deficiency, rasburicase can trigger hemolysis(destruction of RBC) by generating reactive oxygen species that damage red blood cells. As a result, rasburicase is generally contraindicated in patients with G6PD deficiency. If you are diagnosed with this deficiency, inform your physician before taking this medicine because you will be more likely to experience severe haemolytic anaemia or methemoglobinemia(an abnormal form of haemoglobin).

Children who are undergoing chemotherapy for leukaemia, lymphoma, or solid tumor malignancies are at risk for developing hyperuricemia, which can lead to kidney damage, seizures, and other complications. This drug helps to treat hyperuricemia by rapidly reducing the levels of uric acid in the blood.It is important to closely monitor children who are receiving rasburicase for any signs of allergic reactions, hemolysis (breakdown of red blood cells), or any other side effects. This medicine is not recommended during pregnancy as it causes harm to the unborn baby. Tell your healthcare provider before beginning this treatment if you are pregnant or planning to have a baby. It is advised for both men and women to follow proper contraceptive methods during and for 3 months after the last dose of Rasburicase.

Avoid driving and operating heavy machinery if you feel tired or weak during this treatment. Certain activities or conditions that can trigger gout attacks, such as fasting, rapid weight loss, and stress, should also be avoided while taking Rasburicase. Foods that are high in purines should be avoided, such as red meat, organ meats, and some seafood, which can increase uric acid levels and reduce the effectiveness of Rasburicase. It is important to avoid or limit consumption of these foods while taking this medicine. Dehydration can reduce the effectiveness of the medication and increase the risk of side effects, so it is necessary to drink plenty of fluids, especially water, while taking this medicine. Smoking can cause oxidative stress in the body, which can lead to an increase in uric acid levels. It is advised to avoid smoking or using tobacco products while undergoing treatment with Rasburicase.

1. Sanofi-aventis groupe, Electronic Medicines Compendium (EMC), [Revised on Jun 2021] [Accessed on 27th March 2023], https://www.medicines.org.uk/emc/files/pil.12870.pdf
2. Sanofi-aventis U.S. LLC (no date) ELITEK., ELITEK (rasburicase) Powder for solution, for intravenous infusion. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103946s5083lbl.pdf [Accessed on 27th March 2023].
3. Sanofi S.p.A, Fasturtec name of the medicinal product qualitative and quantitative, Available at: https://www.sanofi.com.sg/dam/jcr:e21c742b-05a1-4b24-9d3b-a7d4c646b3bb/143%20Fasturtec%20SG%20FAS%200718%20CCDSv6.pdf [Accessed on 27th March 2023].
4. Ueng, S. (2005) Rasburicase (Elitek): A novel agent for tumor lysis syndrome, Proceedings (Baylor University. Medical Center). U.S. National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1200736/ [Accessed on27th March 2023].
5. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Inflammation, Immunomodulation and Hematopoiesis, pharmacotherapy of gout, 12th edition, 2011, 998.
6. KD Tripathi, Essentials of Medical Pharmacology, Antirheumatoid and antigout drugs, 7th edition, 2013, 217.

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.